In-Market Control of Sun Care Products in Spain
Sun care products play an important role in our daily life, protecting us from the UV rays and their consequences. As a cosmetic product, sunscreens must be safe for humans and need to have the SPF factor they claim. In December 2019, the Spanish AEMPS started a campaign with the aim of guaranteeing that the claimed FPS of sunscreens available in the market are indeed correct and in accordance with testing results.


According to the European Cosmetics Regulation (EC) No 1223/2009, a cosmetic product is defined as “any substance or mixture intended to be placed in contact with the external parts of the human body (epidermis, hair system, nails, lips and external genital organs) or with the teeth and the mucous membranes of the oral cavity with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours”.

In the European Union, sunscreens are within the scope of cosmetic products and must not cause damage to human health when applied under normal or reasonably foreseeable conditions of use (for more information, see our previous post).

Sun care products should contain protection against all dangerous UV (ultraviolet) radiation (UVB and UVA). UVB radiation (shorter) is the main responsible for the inflammation of the skin (‘sun burn’) and the resulting reddening of the skin (erythema). On the other hand, UVA radiation is the main contributor for the cancer risk, and it cannot be neglected.

SPF means “sun protection factor” and it refers only to protection against the radiation which causes erythema (mainly UVB radiation). It is calculated by the ratio of minimum erythemal dose on skin protected by a sunscreen product to the minimum erythemal dose on the same unprotected skin. UVA protection factor means the ratio of minimum UVA dose necessary to induce a persistent pigment darkening on the skin protected by a sunscreen product to the minimal UVA dose necessary to induce the minimal darkening effect on the same unprotected skin.

The efficacy of sunscreen products is an essential factor of its safety and an important public health-issue. The degree of protection should be measured using standardized, reproducible testing methods and take photo-degradation into account. ISO 24444:2019 (which updated ISO 24444:2010) sets global and harmonized guidelines for the in vivo determination of the sun protection factor (SPF) of sunscreen products.

Sun Protection Factor, UVA, critical wavelength and water resistance tests need to be performed in order to ensure such safety and protection of sunscreens.


In December 2019, the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios – AEMPS) started a campaign that consists of an in-market control of sun protection products. The main goal of the campaign was to guarantee that the SPF that appeared on the label did not differ from that determined in the tests. As a result, AEMPS has requested the voluntary withdrawal of 14 sunscreens because their SPF does not match to that on the label.

The campaign focused on sunscreens with SPF 50 or SPF 50+ and a total of 19 products were analysed. The tested sunscreens with novel galenic forms, such as very light creams, mists and sprays, have different price ranges, companies and countries of origin (Spanish, European and non-European), with the objective of having a representative sample. AEMPS evaluation was based on the interpretation of results together with the documentation that is requested to the companies. It performed an in-depth analysis, comparing studies of determination of products’ SPF and the efficacy studies with the labelling claims.

Only 5 of the products had the SPF accordant with the degree indicated on their labels, while the other 14 have not achieved the level claimed on the package. In fact, 5 of these 14 did not exceed 29.9 SPF and the other 9 obtained a value lower than 60, when their label indicated a very high protection category (50+).

Although the sunscreens are within the range of efficacy of high protection category (values between 20-49.9) and there were no incidents of sunburn related to any of these products reported to the Spanish Cosmetovigilance System, the AMPS has urged the companies to voluntary withdraw the batches tested and to carry out additional trials and investigations on other batches to verify the safety of the products. The list of the 14 sunscreens has been made publicly available by the AEMPS.

It is common knowledge that a sunscreen must be safe, protecting us against both UVA and UVB rays. But don’t forget that it also must claim the truth (real SPF) so it can be in accordance with the law and properly inform consumers.

If you have any questions regarding sun care products, SPF and what type of tests you need to perform, do not hesitate to contact us at


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Informe sobre el análisis del FPS de productos de protección solar. Campña de control de mercado 2020. Agencia Española de Medicamentos y Productos Sanitarios. Ministerio de Sanidad. 26 de julio de 2021. Available at:


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »